J&J Plans To Upgrade Recalled OTCs for Relaunch
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson plans to return recalled OTC drugs to the market with innovations designed to strengthen consumer trust, VP of Finance and CFO Dominic Caruso said during a presentation at the Deutsche Bank Securities Health Care Conference.